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The scientifi c symposium entitled The Role of Biofi lm 
in the Treatment of Chronic Ulcer, organized by the 
Croatian Academy of Medical Sciences with support from 
Stoma Medical has demonstrated its educational role. 
This issue of Acta Medica Croatica (AMC) brings current 
concepts on chronic venous disease (CVD), which should 
be acquired by physicians of various specialties, e.g., 
dermatovenereologists, microbiologists, plastic surgeons, 
family physicians, and others. In industrialized countries, 
1%-2% of the population suffer from CVD in lifetime 
(1,2). In Great Britain, health care cost for chronic wound 
treatment amounts to 2.3-3.1 billion pounds per year (3). 
Therefore, this Symposium also has a pharmacoeconomic 
role. The following concepts have been extracted from the 
papers presented at the Symposium:
1. Chronic ulcer (CU) should be approached according 
to the etiologic, anatomic and pathophysiological 
classifi cation of the American Venous Forum (AVF) 
and clinical classifi cation (CEAP). The bacteria present 
in the wound favor the already existing chronic 
infl ammatory reaction, thus stimulating the release of 
enzymes, destroying proteins and reactive metabolites 
of oxygen compounds, as well as the tissue, increasing 
the exudate and capillary permeability; all this leads to 
pain, further maceration, and eventually ulceration. The 
presence of microbes stimulates and sustains further 
tissue damage. Uncontrolled exudate and chronic 
infl ammation with time lead to further aggravation 
of chronic ulcer, which greatly increases the cost of 
treatment. Recent research of the microorganisms 
present in the wound has highlighted the existence of 
biofi lm as the cause of ulcer non-healing (1).
2. The diagnosis of CU should be based on the history, 
physical status and laboratory work-up including 
microbiology, biochemistry, histopathology, radiology, 
oxymetry and ankle index (ABPI) (4-6). 
3. Use of the protocol according to Metcalf, Bowler 
and Hurlow, A clinical algorithm for wound biofi lm 
identifi cation, presented in the whole with the authors’ 
permit, is necessary (5).
4. Prevention and treatment of CVD is nowadays available 
to all patients, from systemic pharmacotherapy, 
compressive therapy (short-elastic and long-
elastic bandages, compressive stockings), physical 
medicine and electrical stimulation (6). Yet, the earlier 
the diagnosis is made, the better is the prognosis and 
reduction in the number of CU patients.
5. Destruction and prevention of biofi lm re-formation, 
along with acting upon the exudate and infection, 
are the advantages achieved by the effi cient action 
of antimicrobial dressings with silver ions and 
disinfectants (7-11).
6. The latest technology of antimicrobial dressings 
with silver and disinfectants has proved useful in 
clinical trials in vitro and in vivo (11). In the USA, it is 
estimated that 17 million people per year are affected 
with chronic infections caused by biofi lm, entailing 
a cost of approximately 94 billion USD (1); therefore, 
signifi cant pharmacoeconomic cost effectiveness 
of this new technology dressings will certainly be 
reported in the near future.
7. In the 21st century, CVD poses a major public health 
problem that considerably reduces the quality of 
life of not only elderly patients (12). Thus, the use of 
the latest generation antimicrobial dressings should 
be quickly introduced. These are optimal dressings 
because they regulate local obstacles in the wound 
management, e.g., excessive exudate, infection and 
biofi lm, by providing protection of the wound and 
adjacent skin, thus favoring wound healing.
8. This thematic AMC issue on chronic ulcer contributes 
to continuous medical education, which is the task of 
the Croatian Academy of Medical Sciences.
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